Novacyt shares jump after launch of new COVID-19 testing products
Reuters
Published Jun 18, 2020 07:33
Updated Jun 18, 2020 08:40
By Sudip Kar-Gupta
PARIS (Reuters) - Healthcare and clinical diagnostics company Novacyt (PA:ALNOV) (L:NCYT), whose shares have surged on the back of its COVID-19 testing products, on Thursday announced the launch of three new products to support testing for the presence of the virus.
The names of the new products are Exsig™ Direct, Exsig™ Mag and COVID-HT, Novacyt said.
The announcement of Novacyt's latest COVID-19 testing products pushed the company's Paris-listed shares up by around 10% by 0710 GMT, with the stock having jumped by around 1,600% since the start of 2020.
"As we continue to supply our COVID-19 test to laboratories around the world, we are delighted to provide further support through the launch of these new products," CEO Graham Mullis said.
Novacyt has singled itself out with a test able to detect the new coronavirus in less than two hours. Standard testing, which also identifies other strains, takes up to a day.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.